Lindus Health hauls in $55M Series B for "anti-CRO"

Lindus Health, a clinical trials research services company billing itself as the "anti-CRO," announced a $55 million Series B.

Why it matters: The company purports to disrupt an industry dominated by a handful of large players with hefty pharma customer pipelines.